Amivantamab

Therapeutic indications

Amivantamab is indicated for:

Advanced non-small cell lung cancer with activating epidermal growth factor receptor

Population group: only adults (18 years old or older)

Amivantamab is indicated as monotherapy for treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

For patients weighting <80 kg 1,050 mg and for patients weighting ≥80 kg 1,400 mg once a week from weeks 1-4 and thereafter once every 2 weeks

Advanced non-small cell lung cancer with activating epidermal growth factor receptor

Population group: only adults (18 years old or older)

Amivantamab is indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

For patients weighting <80 kg 1,400 mg once a week from Week 1-4 and 1,750 mg every 3 weeks starting at Week 7 onwards, and for patients weighting ≥80 kg 1,750 mg once a week from Weeks 1-4 and και 2,100 mg every 3 weeks starting at Week 7 onwards

Advanced non-small cell lung cancer with activating epidermal growth factor receptor

Population group: only adults (18 years old or older)

Amivantamab is indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

For patients weighting <80 kg 1,400 mg once a week from Week 1-4 and 1,750 mg every 3 weeks starting at Week 7 onwards, and for patients weighting ≥80 kg 1,750 mg once a week from Weeks 1-4 and και 2,100 mg every 3 weeks starting at Week 7 onwards

Contraindications

Amivantamab is contraindicated in the following cases:

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

Amivantamab

Therapeutic indications

Advanced non-small cell lung cancer with activating epidermal growth factor receptor

For patients weighting <80 kg 1,050 mg and for patients weighting ≥80 kg 1,400 mg once a week from weeks 1-4 and thereafter once every 2 weeks

Advanced non-small cell lung cancer with activating epidermal growth factor receptor

For patients weighting <80 kg 1,400 mg once a week from Week 1-4 and 1,750 mg every 3 weeks starting at Week 7 onwards, and for patients weighting ≥80 kg 1,750 mg once a week from Weeks 1-4 and και 2,100 mg every 3 weeks starting at Week 7 onwards

Advanced non-small cell lung cancer with activating epidermal growth factor receptor

For patients weighting <80 kg 1,400 mg once a week from Week 1-4 and 1,750 mg every 3 weeks starting at Week 7 onwards, and for patients weighting ≥80 kg 1,750 mg once a week from Weeks 1-4 and και 2,100 mg every 3 weeks starting at Week 7 onwards

Contraindications

Lactation

Get recommendations

Related medicines